journal article·2019-10-22

Near-Infrared II Phototherapy Induces Deep Tissue Immunogenic Cell Death and Potentiates Cancer Immunotherapy

Yinchu Ma, Yuxue Zhang, Xiaoqiu Li, Yangyang Zhao, Min Li, Wei Jiang, Xinfeng Tang, Jiaxiang Dou, Ligong Lu, Feng Wang, Yucai Wang

ACS Nano· Volume 13· Issue 10
Publisher page

Abstract

The deep and inner beds of solid tumors lack lymphocytic infiltration and are subjected to various immune escape mechanisms. Reversing immunosuppression deep within the tumor is vital in clinical cancer therapy, however it remains a huge challenge. In this work, we have demonstrated the use of a second window near-infrared (NIR(II)) photothermal treatment to trigger more homogeneous and deeper immunogenic cancer cell death in solid tumors, thereby eliciting both innate and adaptive immune responses for tumor control and metastasis prevention. Specifically, photothermal transducers with similar components, structures, and photothermal conversion efficiencies, but different absorptions in red light, NIR(I), and NIR(II) biowindows, were constructed by controlling the self-assembly of gold nanoparticles on fluidic liposomes. In vitro, photothermal treatments induced immunogenic cell death (ICD) that were accompanied by the release of damage-associated molecular patterns (DAMPs) regardless of the wavelength of incident lasers. In vivo, NIR(II) light resulted in a more homogeneous release and distribution of DAMPs in the deeper parts of the tumors. With the induction of ICD, NIR(II) photothermal therapy simultaneously triggered both innate and adaptive immune responses and enabled efficient tumor control with 5/8 of the mice remaining tumor-free in the cancer vaccination assay. Additionally, the NIR(II) photothermal treatment in combination with checkpoint blockade therapy exerted long-term tumor control over both primary and distant tumors. Finally, using systemically administered two-dimensional polypyrrole nanosheets as a NIR(II) transducer, we achieved striking therapeutic effects against whole-body tumor metastasis via a synergistic photothermal-immunological response.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People’s Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai 519000, China

Division of Molecular Medicine, Hefei National Laboratory for Physical Sciences at Microscale, the CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230027, China

School of Food and Biological Engineering, Hefei University of Technology, Hefei 230009, China

Funding

Ministry of Education of the People's Republic of China · Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China · Guangdong Province Key Laboratory of Biomedical Engineering, School of Materials Science and Engineering, South China University of Technology

References (52)

Show source-provided references
1. 10.1038/nrc323910.1038/nrc3239 ↗
2. 10.1038/nm110010.1038/nm1100 ↗
3. 10.1056/NEJMe120594310.1056/NEJMe1205943 ↗
4. 10.1038/ni.270310.1038/ni.2703 ↗
5. 10.1126/science.120348610.1126/science.1203486 ↗
6. 10.1016/j.immuni.2013.03.00310.1016/j.immuni.2013.03.003 ↗
7. 10.1016/j.semcancer.2017.03.00110.1016/j.semcancer.2017.03.001 ↗
8. 10.3389/fimmu.2017.0162510.3389/fimmu.2017.01625 ↗
9. 10.1097/CCO.0b013e32831bc38a10.1097/CCO.0b013e32831bc38a ↗
10. 10.1038/nri254510.1038/nri2545 ↗
11. 10.1038/onc.2009.35610.1038/onc.2009.356 ↗
12. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
13. 10.1038/cdd.2013.8410.1038/cdd.2013.84 ↗
14. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
15. 10.1016/j.cyto.2017.05.02410.1016/j.cyto.2017.05.024 ↗
16. 10.1111/imr.1258610.1111/imr.12586 ↗
17. 10.1038/emboj.2009.110.1038/emboj.2009.1 ↗
18. 10.1038/nm152310.1038/nm1523 ↗
19. 10.1038/nrc338010.1038/nrc3380 ↗
20. 10.1038/ncomms1043710.1038/ncomms10437 ↗
21. 10.1002/adma.20160502110.1002/adma.201605021 ↗
22. 10.1002/adma.20160489410.1002/adma.201604894 ↗
23. 10.1021/nn501871d10.1021/nn501871d ↗
24. 10.1021/acsnano.8b0142410.1021/acsnano.8b01424 ↗
25. 10.1021/nn503779d10.1021/nn503779d ↗
26. 10.1021/jacs.8b0036810.1021/jacs.8b00368 ↗
27. 10.1021/acs.nanolett.7b0138210.1021/acs.nanolett.7b01382 ↗
28. 10.1002/adma.20150320110.1002/adma.201503201 ↗
29. 10.1002/anie.20090054510.1002/anie.200900545 ↗
30. 10.1021/ja300140c10.1021/ja300140c ↗
31. 10.1021/jacs.6b0519210.1021/jacs.6b05192 ↗
32. 10.1038/nm.293310.1038/nm.2933 ↗
33. 10.1038/nnano.2015.1710.1038/nnano.2015.17 ↗
34. 10.1021/jacs.6b1184610.1021/jacs.6b11846 ↗
35. 10.1021/jacs.7b0781810.1021/jacs.7b07818 ↗
36. 10.1021/acs.nanolett.7b0467510.1021/acs.nanolett.7b04675 ↗
37. 10.1002/adfm.20180138910.1002/adfm.201801389 ↗
38. 10.1038/s41467-018-03473-910.1038/s41467-018-03473-9 ↗
39. 10.1038/ncomms1319310.1038/ncomms13193 ↗
40. 10.1002/anie.20151178510.1002/anie.201511785 ↗
41. 10.1016/j.cell.2010.02.01510.1016/j.cell.2010.02.015 ↗
42. 10.1038/nm.202810.1038/nm.2028 ↗
43. 10.1016/j.bbcan.2009.08.00310.1016/j.bbcan.2009.08.003 ↗
44. 10.1038/emboj.2011.49710.1038/emboj.2011.497 ↗
45. 10.1158/0008-5472.CAN-09-356610.1158/0008-5472.CAN-09-3566 ↗
46. 10.1155/2013/48216010.1155/2013/482160 ↗
47. 10.4161/21624011.2014.95569110.4161/21624011.2014.955691 ↗
48. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
49. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
50. 10.1038/s41467-017-01651-910.1038/s41467-017-01651-9 ↗
51. 10.4081/oncol.2014.25610.4081/oncol.2014.256 ↗
52. 10.1002/adma.20180300110.1002/adma.201803001 ↗